Corient Private Wealth LLC Acquires 2,784 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Corient Private Wealth LLC raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 34.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,857 shares of the specialty pharmaceutical company's stock after acquiring an additional 2,784 shares during the period. Corient Private Wealth LLC's holdings in Jazz Pharmaceuticals were worth $1,335,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of JAZZ. CIBC Asset Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after acquiring an additional 97 shares during the last quarter. UMB Bank n.a. raised its position in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. grew its holdings in shares of Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after buying an additional 149 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares of the company's stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,022,825 over the last ninety days. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Trading Down 2.8 %

Shares of JAZZ stock traded down $3.48 during trading hours on Friday, hitting $122.92. 1,709,286 shares of the company were exchanged, compared to its average volume of 735,368. The company has a 50 day simple moving average of $132.30 and a two-hundred day simple moving average of $122.54. The firm has a market cap of $7.47 billion, a P/E ratio of 17.31, a P/E/G ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Morgan Stanley reissued an "overweight" rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Piper Sandler reiterated an "overweight" rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.